Develops genetic medicines for neuromuscular and inherited retinal diseases.
Jun 2026Revenue $4.69M/yrExpenses $181M/yr
No trendCash runway ≈ 9 months from Jun 2026
Figures by year
When will Entrada Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $4.69M and expenses $181M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $25.4M | $183M | −$158M |
| Dec 2024 | $211M | $164M | $47.0M |
| Dec 2023 | $129M | $132M | −$3.16M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.